Gout management as part of secondary cardiovascular prevention: A step forward remains necessary to better understanding
AbstractThe paper by Stamp and colleagues (1) contributes to confirming the deleterious role of gout in patients with established cardiovascular (CV) disease. Here this is shown as a shorter time to readmission, mainly for heart failure, but an increased risk of subsequent myocardial infarction, CV ‐related and all‐cause death has also been reported (2). Of interest, these poor outcomes occurred despite appropriate CV management. Gout is a disease with variable levels of inflammation (3), driven by the deposition of monosodium urate crystals.
Publication date: Available online 30 May 2020Source: The Journal of Foot and Ankle SurgeryAuthor(s): Derek S. Anselmo, Lisa Thatcher, David Erfle
Publication date: Available online 30 May 2020Source: PhytomedicineAuthor(s): Jia-Ying Wu, Wai-Chung Leung, Yu-Xi Liu, Xiu-Qiong Fu, Jia-Qian Zhu, Ying Wu, Ji-Yao Chou, Cheng-Le Yin, Ya-Ping Wang, Xiao-Qi Wang, Jing-Xuan Bai, Zheng-Zhi Wu, Zhi-Ling Yu
Publication date: August 2020Source: IJC Heart &Vasculature, Volume 29Author(s): Inder Anand, Jeffrey L. Ardell, Doug Gregory, Imad Libbus, Lorenzo DiCarlo, Rajendra K. Premchand, Kamal Sharma, Sanjay Mittal, Rufino Monteiro
Publication date: Available online 30 May 2020Source: American Heart JournalAuthor(s): Joseph Gibbs, Christopher deFilippi, Frank Peacock, Simon Mahler, Richard Nowak, Robert Christenson, Fred Apple, Gordon Jacobsen, James McCord
Authors: Tzikas S, Papadopoulos C, Evangeliou AP, Vassilikos V PMID: 32470561 [PubMed - as supplied by publisher]
Authors: Versaci F, Scappaticci M, Calcagno S, Del Prete A, Romeo F, Peruzzi M, Cavarretta E, Frati G PMID: 32472994 [PubMed - as supplied by publisher]
AbstractGout is the most common inflammatory arthritis and is often comorbid with cardiovascular disease (CVD). Hyperuricemia and gout are also independent risk factors for cardiovascular events, worsening heart failure (HF), and death. The recommended treatment modalities for gout have important implications for patients with CVD because of varying degrees of cardiovascular and HF benefit and risk. Therefore, it is critical to both manage hyperuricemia with urate-lowering therapy (ULT) and treat acute gout flares while minimizing the risk of adverse cardiovascular events. In this review, the evidence for the safety of pha...
This study shows that mRNA levels of the aging related lamin A splice variant progerin, associated with premature aging in HGPS, were significantly upregulated in subjects with BMI ≥ 25 kg/m2. Moreover, our data revealed a significantly positive correlation of BMI with progerin mRNA. These data provide to our knowledge for the first-time evidence for a possible involvement of progerin in previously observed accelerated aging of overweight and obese individuals potentially limiting their longevity. Our results also showed that progerin mRNA was positively correlated with C-reactive protein (CRP). This might suggest an as...
CONCLUSION: HUC is common in patients with PsA, especially in those with longer disease duration and obesity. Proper control of HUC and metabolic diseases may play a preventive role in improving PsA outcomes. PMID: 29196385 [PubMed - as supplied by publisher]
(Reuters Health) - Sleep apnea may increase the risk of developing gout and experiencing flare-ups, according to a new study. The intense pain and swelling of a joint, often a big toe, that marks gout is caused by the deposition of uric acid crystals in joints and tissues. Sleep apnea, the study team notes, causes periods of oxygen deprivation during the night when people stop breathing, which triggers overproduction of uric acid in the bloodstream. But little was known about the relationship between the two conditions, the study team writes in Arthritis and Rheumatology. In 2007-2008, almost six percent of men and t...